Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L.

Schizophr Res. 2004 Jun 1;68(2-3):283-97.

PMID:
15099610
2.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
3.

Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.

Bralet MC, Falissard B, Neveu X, Lucas-Ross M, Eskenazi AM, Keefe RS.

Eur Psychiatry. 2007 Sep;22(6):365-70. Epub 2007 Apr 16.

PMID:
17434715
4.

Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder.

Chianetta JM, Lefebvre M, LeBlanc R, Grignon S.

Schizophr Res. 2008 Oct;105(1-3):86-94. doi: 10.1016/j.schres.2008.05.024. Epub 2008 Sep 14.

PMID:
18790606
5.

Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.

Mazhari S, Parvaresh N, Eslami Shahrbabaki M, Sadeghi MM, Nakhaee N, Keefe RS.

Psychiatry Clin Neurosci. 2014 Feb;68(2):160-6. doi: 10.1111/pcn.12107. Epub 2013 Oct 31.

6.

Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls.

Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernadez-Egea E, Allas M, Safont G, Contreras F, Gascon J, Soler-Insa PA, Menchon JM, Junque C, Keefe RS.

Eur Psychiatry. 2011 Mar;26(2):69-73. doi: 10.1016/j.eurpsy.2009.11.001.

PMID:
20435446
7.

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.

PMID:
18172019
8.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A.

Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31.

PMID:
21075600
9.

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG.

Arch Gen Psychiatry. 2007 Oct;64(10):1115-22.

PMID:
17909123
10.

Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).

Keefe RS, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins K.

Schizophr Res. 2008 Jul;102(1-3):108-15. doi: 10.1016/j.schres.2008.03.024. Epub 2008 May 20.

PMID:
18495435
11.
12.
13.
14.

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):214-20. doi: 10.1176/appi.ajp.2007.07010043. Epub 2008 Jan 2.

PMID:
18172018
15.

A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.

Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM.

Schizophr Bull. 2011 May;37(3):538-45. doi: 10.1093/schbul/sbp095. Epub 2009 Sep 23.

16.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA.

Am J Psychiatry. 2007 Jul;164(7):1061-71.

17.

Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.

de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F.

Psychiatry Res. 2013 Dec 15;210(2):387-95. doi: 10.1016/j.psychres.2013.06.042. Epub 2013 Jul 30.

PMID:
23910239
19.

Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia.

Fervaha G, Hill C, Agid O, Takeuchi H, Foussias G, Siddiqui I, Kern RS, Remington G.

Schizophr Res. 2015 Aug;166(1-3):304-9. doi: 10.1016/j.schres.2015.05.015. Epub 2015 May 23.

PMID:
26004693
20.

A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.

Silverstein SM, Jaeger J, Donovan-Lepore AM, Wilkniss SM, Savitz A, Malinovsky I, Hawthorne D, Raines S, Carson S, Marcello S, Zukin SR, Furlong S, Dent G.

J Clin Exp Neuropsychol. 2010 Nov;32(9):937-52. doi: 10.1080/13803391003596496. Epub 2010 May 7. Erratum in: J Clin Exp Neuropsychol. 2010 Dec;32(10):1149.

PMID:
20455131
Items per page

Supplemental Content

Write to the Help Desk